Roche’s crovalimab pivotal studies in PNH are positive; poised to be third C5 inhibitor to enter market
HIGH IMPACT – Roche announced positive results from its COMMODORE1 and 2 studies of crovalimab in PNH patients. COMMODORE2 (naïve study) met co-primary endpoint of transfusion avoidance and control of hemolysis (LDH). Crovalimab was non-inferior to eculizumab. COMMODORE1 (switch study) efficacy and safety data supported a favorable benefit-risk profile of crovalimab. Based on these results […]